Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CMPS

Compass Pathways Plc ADR

Dec 08 • 04:00PM ET

6.30

+0.48 8.25 %

Healthcare • Medical Care Facilities • United Kingdom • NASD

Peers: MNMD ATAI CYBN GHRS RLMD AXSM MNOV XENE PRTA TVRD

| Held by: ARKG IBB SURI PSIL GWX SBIO BBC IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.68	Insider Own	1.99%	Shs Outstand	96.00M	Perf Week	20.23%
Market Cap	604.80M	Forward P/E	-	EPS next Y	-1.83	Insider Trans	0.00%	Shs Float	94.09M	Perf Month	12.70%
Enterprise Value	453.66M	PEG	-	EPS next Q	-0.39	Inst Own	57.10%	Short Float	6.64%	Perf Quarter	21.86%
Income	-236.61M	P/S	-	EPS this Y	-1.52%	Inst Trans	5.36%	Short Ratio	3.57	Perf Half Y	34.90%
Sales	0.00M	P/B	16.09	EPS next Y	21.67%	ROA	-94.09%	Short Interest	6.25M	Perf YTD	66.67%
Book/sh	0.39	P/C	3.25	EPS next 5Y	10.40%	ROE	-205.19%	52W High	7.09 -11.08%	Perf Year	52.17%
Cash/sh	1.94	P/FCF	-	EPS past 3/5Y	-8.64% -	ROIC	-406.85%	52W Low	2.25 180.00%	Perf 3Y	-38.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.55% 7.11%	Perf 5Y	-85.88%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-21.62%	Oper. Margin	-	ATR (14)	0.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.02	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	1.23	EPS Q/Q	-152.47%	SMA20	16.27%	Beta	1.96	Target Price	17.00
Payout	-	Debt/Eq	0.94	Sales Q/Q	-	SMA50	6.38%	Rel Volume	1.50	Prev Close	5.82
Employees	166	LT Debt/Eq	0.55	Earnings	Nov 04 BMO	SMA200	40.72%	Avg Volume	1.75M	Price	6.30
IPO	Sep 18, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-264.37% -	Trades		Volume	2,631,090	Change	8.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-25	Downgrade	Evercore ISI	Outperform → In-line	$11 → $6
Feb-27-25	Initiated	Stifel	Buy	$11
Jul-23-24	Initiated	RBC Capital Mkts	Outperform	$23
Apr-01-24	Initiated	Morgan Stanley	Overweight	$30
Dec-12-23	Initiated	Deutsche Bank	Buy	$16
Nov-21-22	Resumed	Berenberg	Buy	$33
Nov-01-22	Initiated	Loop Capital	Buy	$34
Oct-29-21	Initiated	Oppenheimer	Outperform	$50
Jul-13-21	Initiated	Citigroup	Buy	$67
Jun-28-21	Initiated	Maxim Group	Buy	$70
May-11-21	Initiated	Cantor Fitzgerald	Overweight	$71
Apr-01-21	Initiated	ROTH Capital	Buy	$88
Oct-14-20	Initiated	H.C. Wainwright	Buy	$65
Oct-13-20	Initiated	Evercore ISI	Outperform
Oct-13-20	Initiated	Cowen	Outperform
Oct-13-20	Initiated	Canaccord Genuity	Buy	$80
Oct-13-20	Initiated	Berenberg	Buy	$50

Show Previous Ratings

Dec-04-25 04:07PM	Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug (Bloomberg) +11.59%
Nov-20-25 06:30AM	Compass Pathways to Participate in Two Investor Conferences in December (Business Wire)
Nov-05-25 06:30AM	Compass Pathways to Participate in Stifel 2025 Healthcare Conference (Business Wire) -17.19%
Nov-04-25 04:03PM	Compass Pathways PLC (CMPS) Q3 2025 Earnings Call Highlights: Accelerated Launch Plans and ... (GuruFocus.com) +11.43%
06:30AM	Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months (Business Wire)
04:32PM	Loading…
Nov-02-25 04:32PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-30-25 08:30AM	NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression (PR Newswire)
Oct-29-25 06:30AM	Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors (Business Wire)
Oct-28-25 06:30AM	Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 (Business Wire)
Oct-07-25 01:19AM	As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race (Pharma Voice)
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-02-25 06:30AM	Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder (Business Wire)
03:47AM	COMPASS Pathways Plc (CMPS)' Psilocybin Therapy Hits Phase 3 Success in Depression (Insider Monkey)
Aug-27-25 06:30AM	Compass Pathways to Participate in Four Investor Conferences in September (Business Wire)
Aug-25-25 07:50AM	AbbVie wagers more than $1B on Gilgameshs psychedelic drug (BioPharma Dive)
11:55AM	Loading…
Aug-05-25 11:55AM	Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright (TipRanks)
06:30AM	Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA (Business Wire)
Aug-01-25 05:01AM	Compass Pathways PLC (CMPS) Q2 2025 Earnings Call Highlights: Clinical Success and Strategic ... (GuruFocus.com)
Jul-31-25 06:30AM	Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights (Business Wire) +10.41%
Jul-29-25 06:30AM	Compass Pathways Appoints Justin Gover to Board of Directors (Business Wire)
Jul-22-25 06:30AM	Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025 (Business Wire)
Jul-20-25 04:48AM	These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? (Motley Fool)
Jul-15-25 04:58PM	Cathie Wood's ARK Adds 125K COMPASS Pathways plc (CMPS) Shares (Insider Monkey) +10.39%
Jul-10-25 04:00PM	Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET (Business Wire) +5.38%
Jul-08-25 12:00PM	COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why (Zacks)
Jun-29-25 06:01PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:00AM	This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip? (Barchart)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-24-25 07:10AM	Compass stock slips despite psilocybin trial hitting target (Clinical Trials Arena) +7.66%
Jun-23-25 09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg) -49.24%
07:30AM	Loading…
07:30AM	Compass big psychedelic study doesnt impress investors (BioPharma Dive)
06:30AM	Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-18-25 08:30AM	Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 (Newsfile) +7.14%
May-14-25 12:00PM	COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know (Zacks)
06:30AM	Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
03:12AM	Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ... (GuruFocus.com)
May-08-25 06:30AM	Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:34PM	COMPASS Pathways ADS Q1 2025 Earnings Preview (Seeking Alpha)
Apr-29-25 06:30AM	Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities (Business Wire)
Apr-28-25 06:30AM	Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 (Business Wire)
Apr-27-25 03:31PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-25-25 06:13PM	Why Compass Pathways Stock Was a Double-Digit Winner This Week (Motley Fool)
11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
Apr-22-25 06:00AM	Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire) +5.62%
Mar-28-25 05:01PM	This Is a Test From GlobeNewswire (GlobeNewswire)
Mar-26-25 06:30AM	Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-20-25 11:15AM	Lazard International Strategic Equity Portfolio Q4 2024 Commentary (SeekingAlpha)
05:35AM	Lazard International Equity Select Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-18-25 06:30AM	Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire) -6.94%
Mar-11-25 06:30AM	Compass Pathways to Participate in Stifel Virtual CNS Forum (Business Wire)
Mar-05-25 11:06AM	Compass one of the most compelling stories in neuropsych, says H.C. Wainwright (TipRanks)
Mar-01-25 11:15AM	COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
02:11AM	Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ... (GuruFocus.com)
Feb-27-25 03:15PM	Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript (Motley Fool) +5.95%
06:30AM	Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights (Business Wire)
Feb-25-25 04:00PM	Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-18-25 06:30AM	Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025 (Business Wire)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-05-25 06:30AM	Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire) +5.50%
Jan-21-25 06:30AM	Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer (Business Wire)
Jan-10-25 07:01AM	Compass Pathways Announces Pricing of Underwritten Offering (Business Wire) -14.73%
Dec-18-24 06:30AM	Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) (Business Wire) -6.43%
Nov-29-24 08:57PM	Is Your Mind Ready to Consider Investing in Psychedelics Stocks? (Motley Fool)
Nov-25-24 04:00PM	Compass Pathways to Participate in December Investor Conferences (Business Wire)
Nov-14-24 07:44AM	Compass Pathways to participate in Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-02-24 09:25AM	Compass Pathways cuts 30% of workforce on Phase 3 trial delays (TipRanks)
Nov-01-24 11:00AM	Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Oct-31-24 09:00PM	Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript (Motley Fool) -23.10%
08:03AM	Compass delays anticipated psilocybin readout, cuts staff (BioPharma Dive)
06:30AM	Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Oct-24-24 06:30AM	Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 (Business Wire)
Sep-23-24 07:00AM	Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Aug-28-24 06:00AM	Compass Pathways to participate in three investor conferences in September (GlobeNewswire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-19-24 07:13AM	More promise for psilocybin in depression but safety remains a concern (Clinical Trials Arena)
Aug-12-24 12:47PM	FDA Rejection of MDMA Therapy Isnt End of Psychedelic-Drug Candidates (Barrons.com)
Aug-06-24 08:00AM	COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 11:30PM	Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript (Motley Fool) -9.83%
06:30AM	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
Jul-28-24 06:05PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-24-24 07:01AM	Compass Pathways to announce second quarter financial results on August 1, 2024 (GlobeNewswire)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +9.39%
Jul-08-24 07:45AM	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers (InvestorPlace)
Jul-02-24 03:43PM	3 Psychedelic Stocks to Buy on the Dip: Summer 2024 (InvestorPlace)
Jun-26-24 06:30AM	Compass Pathways appoints Lori Englebert as Chief Commercial Officer (GlobeNewswire)
Jun-24-24 04:01PM	Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-12-24 06:25AM	Should You Buy the Dip on Compass Pathways Stock? (Motley Fool) +7.04%
Jun-10-24 08:25AM	Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. (Motley Fool) -5.62%
Jun-09-24 06:14PM	After FDA setback, psychedelic drugmakers distance themselves from a pioneer (Washington Post)
Jun-05-24 11:42AM	Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate (The Wall Street Journal)
May-21-24 08:05AM	These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring (Motley Fool)
May-13-24 10:43AM	COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript (Insider Monkey)

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMPS

Compass Pathways Plc ADR

Upgrade your FINVIZ experience